Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 08-03 22:06:41时区推断·⟳ 抓取 08-03 22:07:32·⚡ 决策 08-04 06:56:07 +8h48m·84.6 天前
阿斯利康7月员工计划新增上市8,855股，摊薄影响极小
阿斯利康本次新增上市8,855股普通股，用于员工股份计划。
📄 原文Investing.com↗ 原文
AstraZeneca admits 8,855 shares under employee schemes
Oil falls over 5% as Trump calls off Iran strike, announces fresh talks LONDON - AstraZeneca PLC (LSE:AZN) admitted 8,8…
不做 阿斯利康（AZN.GB）
8,855股员工计划新增上市规模极小，仅约总股本0.00057%，属于例行行政披露，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 low ↗
关键理由
- 阿斯利康本次新增上市8,855股普通股，用于员工股份计划。
- 相对已发行股份1,551,033,389股，本次新增约0.00057%，对股本、流动性和基本面影响可忽略。
主要风险
- 正文与标题存在明显错配，标题为油价和伊朗消息，正文为阿斯利康股份计划公告。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,240 字
Oil falls over 5% as Trump calls off Iran strike, announces fresh talks
LONDON - AstraZeneca PLC (LSE:AZN) admitted 8,855 ordinary shares to trading on the London Stock Exchange’s Main Market during July, according to a press release statement.
The shares, valued at $0.25 each, were issued under the company’s employee share schemes between July 1 and July 31. The admission occurred under a block admission dated January 29, 2021.
Following the admission, AstraZeneca’s total number of ordinary shares in issue stands at 1,551,033,389. The newly issued shares are fully fungible with existing ordinary shares under ISIN GB0009895292.
The notification was made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R. No prospectus or supplementary documentation was required for the admission.
AstraZeneca is a biopharmaceutical company based in Cambridge, UK, that focuses on prescription medicines in oncology, rare disease, and biopharmaceuticals. The company’s shares trade on the London Stock Exchange, Stockholm Stock Exchange, and New York Stock Exchange under the ticker AZN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LONDON - AstraZeneca PLC (LSE:AZN) admitted 8,855 ordinary shares to trading on the London Stock Exchange’s Main Market during July, according to a press release statement.
The shares, valued at $0.25 each, were issued under the company’s employee share schemes between July 1 and July 31. The admission occurred under a block admission dated January 29, 2021.
Following the admission, AstraZeneca’s total number of ordinary shares in issue stands at 1,551,033,389. The newly issued shares are fully fungible with existing ordinary shares under ISIN GB0009895292.
The notification was made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R. No prospectus or supplementary documentation was required for the admission.
AstraZeneca is a biopharmaceutical company based in Cambridge, UK, that focuses on prescription medicines in oncology, rare disease, and biopharmaceuticals. The company’s shares trade on the London Stock Exchange, Stockholm Stock Exchange, and New York Stock Exchange under the ticker AZN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。